Founded in 2018 as a DNA extraction chemistry company, Dutch company MolGen entered the market operating within the agricultural sector. At first, the company’s founders, Maarten de Groot, Wim van Haeringen and Niels Kruize, focused solely on this one industry, mainly developing and marketing advanced bulk chemistry kits for DNA/RNA extraction. These testing products and solutions successfully satisfied the needs of the seed and plant breeding industry. Things changed drastically for the company, though, with the unexpected arrival of the COVID-19 pandemic.
Knowing it had as a strong experience as a DNA extraction chemistry company and years of experience in life sciences, MolGen responded to an invitation by the Ministry of Health, Welfare and Sport to offer a solution of procuring and supplying testing equipment to the Dutch government. Soon MolGen was supplying mobile labs and consumables for public health authority test centers in cities including Amsterdam, Rotterdam, and Utrecht.
In the area of human and animal diagnostics applications, MolGen develops and globally markets an advanced molecular total solution that has several applications – from the diagnosis of SARS-COV2 to generic variant screening to Influenzae screening and other applications. Its extraction and testing solutions, products and equipment are designed to achieve increased automation, reduced laboratory time, high yields and reproducibility. Now able to test everything from blood to cultured cells to bacteria to tissue and cell-free body fluids, MolGen’s throughput workflows enable the creation of future-ready, professional-grade laboratories that feature specialized components that leverage highly-effective protocols that improve workflow, safety and results rate.
Leaning into its legacy capability, MolGen continues to offer advanced extraction and testing products and solutions directed at the agriculture industries. Expanding the company’s impact further is its investment in biotech solutions directed at the genetics branch across the food, pharma and biopharma industries.
In June 2021, SpeeDx Pty, Ltd. and MolGen announced the signing of an agreement to collaborate on supply and distribution of clinical diagnostics products and instrumentation across Europe and Asia Pacific. The partnership links specimen handling, nucleic acid extraction, assay set-up, amplification, and results reporting in a seamless integration of the companies technologies.
While the company has established long-term partnerships with large renown service laboratories, scaling up their SARS-CoV-2 test capacity successfully, MolGen is now expanding internationally, bringing its DNA/RNA Extraction product offering to the US market. An office has already been opened in the United States and in the United Kingdom, while a logistics hub in China will be established by the end of 2021.
The tremendous growth by MolGen has only strengthened the company’s resolve to find even more avenues for partnership in order to create greater cost efficiencies and bring the most advanced equipment to laboratories and emerging markets around the world.
From sample to result, MolGen is challenging the status quo in molecular diagnostics by offering high-tech, automated systems and consumables, and combining multiple systems into complete diagnostical flows that are high-quality, adaptable and safe.
MolGen The Netherlands
3905 NL, Veenendaal
P.O. box 3014
3502 GA UTRECHT
Chamber of Commerce address:
3905 NR, Veenendaal
Chamber of Commerce: 71926739
VAT number: 858906831B01
MolGen USA, LLC
7955 Dunbrook Rd Ste I
San Diego, CA 92126
T: +1 888 MOLGEN1
MolGen UK, LTD
6th Floor, South Quay Building 189 Marsh Wall